The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
C21 Investments Inc. is a vertically integrated cannabis company with newly acquired operations in Oregon, U.S.A. C21’s strategy is to acquire existing cannabis operations in the U.S.A. and globally, with experienced management teams in place. C21’s focus is to expand where it can wholly own indoor/outdoor cultivation operations, processing/extraction facilities, bakeries, branded products, and retail dispensaries with a large distribution network.
Canada House Wellness Group Inc. (the “Company”) is the parent company of 672800 NB Inc. doing business as Marijuana for Trauma Inc., Knalysis Technologies Inc. and Abba Medix Corp. Through their vertically integrated subsidiaries, the Company’s goal is to become a marketplace leader in the delivery and support of evidence based, client focused cannabinoid therapy. For more information please visit www.canadahouse.ca.
The Issuer is an investment corporation which seeks to provide shareholders long-term total return through capital appreciation by investing in an actively managed portfolio of securities of public and private companies operating in, or that derive a significant portion of their revenue or earnings from, products or services related to the cannabis industry.
Cannex was founded in 2017 and is managed by a team of experienced industry and capital markets experts who are committed to aggressive, cost-effective growth. Cannex intends to facilitate growth through cash flow from operations, strategic acquisitions and partnerships and by leveraging the expertise of its experienced operational team. Cannex will focus on providing a range of comprehensive and flexible growth options for licensed cannabis cultivators, processors and/or dispensaries domestically and internationally, including providing turn-key real estate with operational infrastructure as well as long term advisory and consulting services.
Class A Shares
The total number of outstanding shares does not include 96,521,733 Class A convertible restricted voting shares (the “Class A Shares”) that are issued and outstanding. The Class A Shares are held by U.S. residents and there are restrictions on the ability of U.S. residents to convert such shares into common shares.
The holders of the Class A Shares are entitled to receive notice of and to attend all meetings of the shareholders. The holders of Class A Shares are entitled to one vote per Class A Share at any meeting of the shareholders provided that the holders of the Class A Shares will not be entitled to vote for the election or removal of the directors. Please see Section 10 – Description of Securities, of Cannex’s Form 2A Listing Statement for a further description of the Class A Shares.
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the "Medical" into medicinal cannabis.
Choom Holdings, together with its wholly-owned subsidiary, Medi-Can Health Solutions Ltd., a cannabis production license applicant under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), intends to develop a unique lifestyle brand for cannabis for Canada’s emerging cannabis market.
ChroMedX Corp. is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT)
Cognetivity Neurosciences Ltd. is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.